Nicox SA said that its partner has received approval in Canada of VYZULTA (latanoprostene bunod ophthalmic solution), 0.024%.
Bausch + Lomb, a global eye health company and wholly owned subsidiary of Bausch Health Companies Inc. (BHC,BHC.TO) and exclusive global licensee for VYZULTATM, announced the approval yesterday. VYZULTATM is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Nicox receives increasing tiered net royalties of 6% to 12% on global sales of VYZULTATM as well as up to $150 million in net sales milestones linked to global sales.
Source: Read Full Article